Lead Product(s) : Tetrabenazine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fed Conditions
Details : Tetrabenazine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 11, 2018
Lead Product(s) : Tetrabenazine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrabenazine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Tetrabenazine Tablets 25 mg Under Fasting Conditions
Details : Tetrabenazine is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 04, 2018
Lead Product(s) : Tetrabenazine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrabenazine
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tetrabenazine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Huntington Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 28, 2015
Lead Product(s) : Tetrabenazine
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : H. Lundbeck AS
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tetrabenazine
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tetrabenazine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Tourette Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 28, 2010
Lead Product(s) : Tetrabenazine
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
